AstraZeneca’s Oral PCSK9 Inhibitor Shows Promise in Reducing Cholesterol Levels
AstraZeneca announced positive results from a phase 2 trial of its oral small molecule PCSK9 inhibitor, AZD0780. The study found that the highest dose of 30mg daily reduced low-density lipoprotein cholesterol (LDL-C) levels by 50.7% after 12 weeks in patients with lipid disorder. This is comparable to other treatments available on the market. The trial … Read more